AccuStem Brings MSC Blood Test to Lung Cancer Screening
AccuStem Sciences, Inc. (OTCQB: ACUT), a pioneering clinical stage diagnostics company, is set to launch its innovative microRNA Signature Classifier (MSC) blood test, targeting over 1.6 million individuals diagnosed with lung nodules each year in the U.S. This initiative aims to enhance the existing lung cancer screening programs and reach out to the 15 million patients identified as at risk annually.
Lung Cancer: A Global Challenge
Lung cancer remains the most prevalent cancer worldwide, with approximately 2.5 million new cases each year. Tragically, it accounts for 1 in 5 cancer-related fatalities, primarily due to its late-stage diagnosis. In response, the recommendation for low-dose computed tomography (LDCT) scanning has emerged as a critical step in improving early detection. This recommendation follows successful outcomes from the National Lung Screening Trial, which showcased a 20% reduction in lung cancer mortality among high-risk groups utilizing LDCT. However, adoption of these programs has been slow, although recent reports show a surge in screenings as public awareness grows.
Addressing False Positives in Lung Cancer Diagnosis
Despite LDCT's effectiveness as a non-invasive detection method, false positives remain a significant concern. To combat this challenge, researchers at the Istituto Nazionale Tumori (INT) have created a game-changing diagnostic tool—the MSC test. This test evaluates various microRNAs (miRNAs) from a blood sample and has undergone comprehensive evaluations in over 5,000 patients through multiple clinical trials. Notably, a significant study published in the Journal of Clinical Oncology reported that combining LDCT with the MSC test reduced the false positive rate from 19.4% to an impressive 3.7%, demonstrating a five-fold improvement in accuracy.
Clinical Validation and Results
Ugo Pastorino, MD, a thoracic surgeon and principal investigator in the BioMILD trial, expressed excitement over the findings, noting that MSC positive patients are more than four times likely to have or develop lung cancer compared to those who test negative. The data published in The Lancet Regional Health – Europe further validates the integral role of MSC in optimizing lung cancer screening protocols.
Healthcare Cost-Benefits of MSC
Insights from the test's inventors—Dr. Gabriella Sozzi, Dr. Mattia Boeri, and Dr. Ugo Pastorino—indicate that MSC can precisely categorize patients with lung nodules. This advancement could lead to substantial healthcare savings by minimizing unnecessary biopsies, which are often both invasive and costly. Currently, MSC is being utilized in the RISP clinical trial, as AccuStem gears up for its commercialization in the U.S. by 2026.
CEO Wendy Blosser's Vision
AccuStem's CEO, Wendy Blosser, recognizes the considerable potential for the MSC test in improving the healthcare experience for the 1.6 million patients diagnosed with lung nodules annually. With plans to broaden test usage to all at-risk individuals, MSC could play a vital role in pre-screening—potentially benefiting the estimated 15 million patients identified as high-risk for lung cancer in the United States each year.
About AccuStem Sciences
AccuStem is dedicated to transforming cancer treatment through innovative diagnostics aimed at enhancing patient outcomes and quality of life. By employing groundbreaking molecular testing, the company addresses significant clinical challenges from screening to ongoing treatment. By exploring novel disease pathways, especially tumor “stemness,” AccuStem aspires to equip healthcare professionals with critical insights into each individual's cancer biology, fostering informed and effective treatment decisions.
Frequently Asked Questions
What is the MSC blood test?
The MSC blood test is a diagnostic tool that evaluates microRNAs in blood samples to identify individuals at risk of lung cancer.
How does the MSC test improve lung cancer screening?
By reducing false positive rates when combined with LDCT, the MSC test enhances diagnostic accuracy, allowing for better patient stratification.
When does AccuStem plan to commercialize the MSC test?
AccuStem aims to launch the MSC blood test in the U.S. in 2026.
Who can benefit from the MSC blood test?
Patients diagnosed with lung nodules and high-risk individuals for lung cancer are the primary beneficiaries of the MSC test.
What role does AccuStem play in cancer diagnostics?
AccuStem focuses on developing innovative diagnostic solutions that address unmet needs in cancer detection and treatment, ultimately enhancing patient care.
